SmithKline Beecham
GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints
Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance
iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial
iTeos Therapeutics, GSK, TIGIT, EOS-448, Jemperli, Phase 2 trial, tumor shrinkage, immuno-oncology, cancer treatment
GSK Advances mRNA Flu Vaccine to Late-Stage Clinical Development Following Positive Phase II Results
GSK, mRNA flu vaccine, phase II results, late-stage clinical development, influenza A and B strains, vaccine efficacy, safety profile.
GSK’s Therapeutic Herpes Vaccine Fails to Meet Efficacy Objective in Phase I/II Trial
GSK, therapeutic herpes vaccine, herpes simplex virus, HSV, vaccine failure, clinical trial
GSK Abandons HSV Vaccine Development After Phase 2 Failure, Paving Way for Moderna and BioNTech
GSK, HSV vaccine, phase 2 failure, Moderna, BioNTech, mRNA vaccines, herpes simplex virus
GSK to Close UK Antibiotic Factory in Ulverston Following Sandoz Contract Termination
GSK, Ulverston, antibiotic factory, Sandoz contract, closure, job losses
GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half
GSK, Depemokimab, Asthma, Phase 3 Trials, Long-Acting Biologic, IL-5 Inhibitor, Severe Asthma, Type 2 Inflammation
GSK’s Nucala Demonstrates Efficacy in COPD with Positive Phase III Trial Results
GSK, Nucala, COPD, Phase III trial, mepolizumab, chronic obstructive pulmonary disease, asthma, IL-5 antagonist, monoclonal antibody.
GSK Secures Another Legal Victory in Latest Zantac Verdict
GSK, Zantac, legal victory, cancer claims, ranitidine, NDMA, FDA, pharmaceutical litigation
Impact of New CDC Guidelines on RSV Vaccine Makers
RSV vaccine, CDC guidelines, vaccine makers, Moderna, Pfizer, GSK, Guillain-Barré syndrome, vaccination recommendations